Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma
The autoantigens of a new category of treatment‐responsive paraneoplastic encephalitis are reported, and it is proposed that this category should be combined with existing treatment-responsive encephalopathy categories.
Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Once considered an extremely rare disorder, almost always related to cancer, and refractory to treatment, limbic encephalitis is now regarded as a relatively frequent disorder, often unrelated to cancer and with clinical-immunologic variants that respond to treatment.
Potassium channel antibodies in two patients with reversible limbic encephalitis
- C. Buckley, J. Oger, A. Vincent
- Medicine, BiologyAnnals of Neurology
- 1 July 2001
It is suggested that patients with limbic symptoms and excessive secretions should be tested for VGKC antibodies, and, if they are present, prompt and effective immunosuppressive treatment should be considered.
Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma
- E. Tüzün, Lei Zhou, J. Baehring, S. Bannykh, M. Rosenfeld, J. Dalmau
- Biology, MedicineActa Neuropathologica
- 14 August 2009
Findings coupled with recently reported in vitro data showing that antibodies downregulate the levels of NMDA receptors suggest that the antibody immune-response is more relevant than cytotoxic T-cell mechanisms in the pathogenesis of anti-NMDAR-associated encephalitis.
A patient with encephalitis associated with NMDA receptor antibodies
- L. Sansing, E. Tüzün, M. Ko, Jennifer Baccon, D. Lynch, J. Dalmau
- MedicineNature Clinical Practice Neurology
- 1 May 2007
Paraneoplastic encephalitis associated with immature teratoma of the ovary and N-methyl-D-aspartate receptor antibodies is associated with prominent autonomic instability requiring intubation and sedation.
Epigenetics of Multiple Sclerosis: An Updated Review
- C. Küçükali, M. Kürtüncü, A. Çoban, M. Çebi, E. Tüzün
- BiologyNeuromolecular medicine
- 1 June 2015
Ongoing efforts in this field are expected to result in characterization of epigenetic factors that can be used in prediction of treatment responsive MS patients, diagnostic screening panels and treatment methods with specific mechanism of action.
Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis 1
- E. Tüzün, Benjamin G. Scott, E. Goluszko, S. Higgs, P. Christadoss
- Biology, MedicineJournal of Immunology
- 1 October 2003
In vivo evidence is provided for the first direct genetic evidence for the classical complement pathway in the induction of EAMG induced by AChR immunization, suggesting that severe MG and other Ab- and complement-mediated diseases could be effectively treated by inhibiting C4, thus leaving the alternative complement pathway intact.
Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production1
- C. Deng, E. Goluszko, E. Tüzün, Huan Yang, P. Christadoss
- Biology, MedicineJournal of Immunology
- 15 July 2002
EAMG resistance in IL-6−/− mice was associated with a significant reduction in germinal center formation and decreased serum complement C3 levels, and AChR-specific lymphocyte proliferative response, IFN-γ, and IL-10 production were suppressed.
Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica Patients
- Sema İİçöz, E. Tüzün, G. Akman-Demır
- Medicine, BiologyInternational Journal of Neuroscience
- 1 January 2010
The results suggest that IL-6 is involved in NMO pathogenesis presumably viaAnti-Aqp-4 associated mechanisms, and serum/CSF IL- 6 levels correlated with anti-Aquaporin-4 levels and disease severity of the NMO patients.
Complement and cytokine based therapeutic strategies in myasthenia gravis.
- E. Tüzün, R. Huda, P. Christadoss
- Biology, MedicineJournal of Autoimmunity
- 1 September 2011
...
...